Project Grant R15HL188532
Award Date 8/15/26
Completion Date 4/30/29
Dollars Obligated $552K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dayton, OH 45435, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Wisconsin - Madison $1.211 million on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate neutral sphingomyelinase (NSMASE) in cardiac mechanosensing and mechanical regulation of the heart. The project addresses NSMASE as a critical membrane enzyme involved in sphingolipid metabolism that regulates both normal physiological heart function in response to acute changes in cardiac...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $729,984 under the Cardiovascular Diseases Research program (CFDA 93.837) on July 22, 2026. The award funds development of a three-dimensional real-time cardiovascular magnetic resonance imaging (3D RT CMR) reconstruction framework for imaging patients with cardiac arrhythmias. The proposed unsupervised reconstruction method, called Generative Prior with Multi-Dynamic Modeling (GEMM), enables highly accelerated 3D RT...
- The National Heart, Lung, and Blood Institute awarded the University of Cincinnati Sponsored Research Services Division $1.57 million on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on targeted rewiring of fibrosis drivers to enhance cardiac reprogramming following myocardial infarction. The research addresses excessive cardiac fibrosis resulting from the heart's repair response, which can lead to adverse remodeling and heart failure. The...
- The National Heart, Lung, and Blood Institute awarded The Washington University $764,681 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 1, 2026, to conduct research into a multipotent fibroblast population and platelet-derived growth factor receptor beta–dependent immuno-fibrotic responses in heart failure. The research addresses cardiac fibrosis and left ventricular dysfunction in heart failure by investigating a novel population of stem cell antigen-1–expressing,...
- The National Heart, Lung, and Blood Institute awarded the University of Toledo $561,300 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026. The award funds research into the ERK1/2-C-FOS/EGR1/2 pathway in GFI1- and C/EBP-mediated granulopoiesis, specifically investigating how transcription factors GFI1 and C/EBPA promote neutrophil development. The research will test hypotheses that these factors instruct neutrophil fate in part through negatively regulating...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $776,745 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and target DELE1-mediated mitochondrial stress signaling in cardiomyopathy. The research addresses how mitochondrial dysfunction drives cardiovascular disease, including heart failure and ischemic injury, by characterizing the molecular mechanisms through which DELE1 acts as a mitochondrial stress sensor to...
- The National Heart, Lung, and Blood Institute awarded the University of Wisconsin–Madison $151,040 on February 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the assembly and localization of HERG channel cotranslational complexes in cardiac tissue. The research examines how heart cells co-regulate functionally related ion channels at the translational level during protein biosynthesis, with focus on HERG1A and HERG1B channel assembly. The project uses...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $1,574,578 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel targeted modified mRNA delivery strategies for donation after circulatory death (DCD) heart transplantation. The research addresses primary graft dysfunction (PGD), an ischemia-reperfusion injury occurring in approximately 35 percent of heart transplants and driven by hyper-inflammatory responses involving...
- The National Heart, Lung, and Blood Institute awarded Case Western Reserve University $4,349,952 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the phosphorylation-based molecular and functional mechanisms by which cardiac myosin binding protein C (CMYBP-C) modulates cardiac contractile function. The research employs a multidisciplinary experimental approach spanning atomic to whole-organ scales to determine how CMYBP-C conformational changes in...
- The National Heart, Lung, and Blood Institute awarded $108,656 to the University of Wisconsin–Madison on March 3, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize the molecular mechanisms of phospholamban R14DEL cardiomyopathy. The recipient will use high-resolution mass spectrometry–based proteomics, human clinical samples, and patient-specific human induced pluripotent stem cell–derived cardiomyocytes to investigate how cardiac proteoform alterations drive...